Bacillus Calmette-Guérin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mechanisms of BCG immunotherapy and its outlook for bladder cancer

(2018) Caroline Pettenati et al.   Nature Reviews Urology

Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guérin: experience of a single center

(2018) Rodolfo Hurle et al.   Minerva Urologica E Nefrologica

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

(2017) Marko Babjuk et al.   EUROPEAN UROLOGY

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) Philippe E. Spiess et al.   Journal of the National Comprehensive Cancer Network

Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate–high-risk non-muscle-invasive bladder cancer

(2016) Alejandro Sousa et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

(2016) Ashish M. Kamat et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

(2016) Sam S. Chang et al.   JOURNAL OF UROLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer

(2016) Kyla N. Velaer et al.   Current Urology Reports

Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy

(2015) Marco Moschini et al.   BJU INTERNATIONAL

CUA guidelines on the management of non-muscle invasive bladder cancer

(2015) Wassim Kassouf et al.   CUAJ-Canadian Urological Association Journal

Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non–muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013

(2015) Luis Martínez-Piñeiro et al.   EUROPEAN UROLOGY

Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-Guérin

(2015) Alvaro Morales et al.   JOURNAL OF UROLOGY

Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer

(2014) Ashish M. Kamat et al.   JOURNAL OF UROLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis

(2013) Rodney H. Breau et al.   BJU INTERNATIONAL

Maintenance Bacillus Calmette-Guérin Treatment of Non–muscle-invasive Bladder Cancer: A Critical Evaluation of the Evidence

(2013) Behfar Ehdaie et al.   EUROPEAN UROLOGY

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

(2013) Maurizio Brausi et al.   EUROPEAN UROLOGY

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin

(2013) Eila C. Skinner et al.   JOURNAL OF UROLOGY

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

(2013) Colin P.N. Dinney et al.   JOURNAL OF UROLOGY

The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guérin

(2013) John P. Sfakianos et al.   JOURNAL OF UROLOGY

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer

(2013) Andrew J. Lightfoot et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The Effect of Fibrin Clot Inhibitors on the Immunomodulatory Efficacy of Bacillus Calmette-Guérin Therapy for Non–muscle-invasive Bladder Cancer

(2013) Michael J. Lipsky et al.   UROLOGY

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

(2012) Jorg Oddens et al.   EUROPEAN UROLOGY

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

(2012) James M. Burke et al.   JOURNAL OF UROLOGY

Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy

(2012) LaMont J. Barlow et al.   JOURNAL OF UROLOGY

Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer

(2012) C. Biot et al.   Science Translational Medicine

Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin

(2012) Colin P.N. Dinney et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity

(2012) Yi Luo   OncoImmunology

Markers Predicting Response to Bacillus Calmette-Guérin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review

(2011) Tahlita C.M. Zuiverloon et al.   EUROPEAN UROLOGY

An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

(2009) Per-Uno Malmström et al.   EUROPEAN UROLOGY

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

(2009) Richard J. Sylvester et al.   EUROPEAN UROLOGY

Fibrin Clot Inhibitor Medication and Efficacy of Bacillus Calmette-Guerin for Bladder Urothelial Cancer

(2009) Stephen A. Boorjian et al.   JOURNAL OF UROLOGY

Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer

(2009) Aurélie Bisiaux et al.   JOURNAL OF UROLOGY

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

(2008) J. L. Gulley et al.   CLINICAL CANCER RESEARCH

Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group

(2008) Jeffrey M. Ignatoff et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS